

2023 Independent Medical Education Request for Proposal

Release Date: June 12, 2023

Puma Biotechnology invites accredited educational providers to submit grant requests for independent, certified medical education grants per to the terms described below. This Request for Proposal (RFP) provides public notice of the availability of funds in a general topic area for activities with recognized scientific or educational needs.

Purpose: As part of Puma Biotechnology’s scientific mission, we provide grants for independent medical education (IME) that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance. Puma Biotechnology does not control or influence the content of any supported IME programs, nor the selection of speakers, authors, or faculty planners involved with the grant-supported programming.

Notification: Puma RFPs are made available through the Puma IME website (https://pumabiotechnology.com/independent_medical_education.html) along with the website for the Alliance for Continuing Education in the Health Professions (ACEhp). In addition, Puma sends an email to all registered Puma IME portal users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our Puma IME website to stay informed of current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this RFP will be reviewed in accordance with Puma policies. (Please refer to the publicly available criteria on https://pumabiotechnology.com/independent_medical_education.html)
2. All grant requests submitted in response to this RFP must be routed exclusively to Puma’s Independent Medical Education team through the Puma IME Portal: <https://www.cybergrants.com/pumabio/mededquiz>. Failure to comply will automatically disqualify providers.
3. **Grant requests must be clearly labeled as responses to this RFP.**
4. This RFP does not commit Puma to award a grant or pay any costs incurred in the preparation of a response to this request.
5. Puma reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this RFP.
6. Deadlines associated with this RFP may be subject to change at Puma’s discretion.
7. Failure to follow the instructions within this RFP may result in a denial.
8. Applicants may reach out to IME@pumabiotechnology.com with questions.

Instructions

Eligibility Criteria	<ul style="list-style-type: none">• US-based education provider• Registered Puma IME Portal account• Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	<ul style="list-style-type: none">• US-based only

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this RFP will have 6 weeks to complete a full application	August 1, 2023
Step 2	Puma will review in a timely manner and provide notification of final decisions via the funding portal	
Step 3	We seek timeliness with this education and ask that all educational programs are launched by the Fall of 2023	Nov 1, 2023

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider’s understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Currently Available RFP Focus Area:

Therapeutic Area	Oncology / HER2-positive Early-Stage Breast Cancer
Learning Objective	<p>The clinical data for all of oncology, including in HER2-positive early breast cancer (EBC), is evolving at a rapid pace.^{1,2} Puma Biotechnology is committed to supporting healthcare providers to stay informed of advances in this area, including regarding the role of extended adjuvant therapy in reducing recurrences and death.³</p> <p>Despite the successful incorporation of HER2-targeted agents in EBC, considerable numbers of women still recur. The Phase 3 KATHERINE trial of adjuvant ado-trastuzumab emtansine (T-DM1; n=743) versus trastuzumab (n=743) for patients with EBC and residual disease following neoadjuvant chemotherapy (no pathologic complete response [pCR]), demonstrated recurrence rates of 11.7% in the T-DM1 arm and 23.0% in the trastuzumab arm at 3 years follow-up.⁴</p> <p>Puma is seeking education focused on helping community healthcare providers to 1) understand recurrence rates amongst patients with high-risk HER2-positive EBC and 2) increase knowledge and competence in their ability to identify high-risk patients who may benefit from extended adjuvant therapy.</p>
Learning Audience	Community-based HCPs
Educational Format	Knowledge- and competence-based regional and local education (<i>understanding and addressing national or local gaps and emerging data</i>). Puma will consider funding a variety of learning formats, including online, audio, in-person, and video programs.
Support Available	Maximum \$250,000; requests of lower amounts will be equivalently reviewed
References	<ol style="list-style-type: none"> 1. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer version v3.2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf 2. Doximity. Physician Learning Preferences. Oct 2022 https://c8y.doxcdn.com/image/upload/Press%20Blog/Research%20Reports/Doximity-Physician-Learning-Report-2022.pdf 3. Jackisch C, Cortazar P, Geyer CE Jr, et al. Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. <i>Cancer Treat Rev.</i> 2021 PMID: 34139476 DOI: 10.1016/j.ctrv.2021.102229 4. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. <i>N Engl J Med.</i> 2019 Feb 14;380(7):617-628. PMID: 30516102 DOI: 10.1056/NEJMoa1814017